Evidence map›Paper›PMID 33861431›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Mutations in chronic myelomonocytic leukemia and their prognostic relevance.

J Jian, Y Qiao, Y Li, Y Guo, H Ma, B Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Epigenetic alterations in Myeloid Malignancies.Advances in experimental medicine and biology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

J Jian *The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.
Y Qiao *Institute of Hematology, Xi'an Central Hospital, Xi'an, Shaanxi, China.
Y LiThe First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.
Y GuoThe First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.
H MaThe First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China. mahaizhen-2008@163.com.
B LiuThe First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China. liubeiff@163.com.ORCID http://orcid.org/0000-0003-4331-2138
Lanzhou University · CNFirst Hospital of Lanzhou University · CNXian Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy that overlaps with myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) and tends to transform into acute myeloid leukemia (AML). Among cases of CMML, > 90% have gene mutations, primarily involving TET2 (~ 60%), ASXL1 (~ 40%), SRSF2 (~ 50%), and the RAS pathways (~ 30%). These gene mutations are associated with both the clinical phenotypes and the prognosis of CMML, special CMML variants and pre-phases of CMML. Cytogenetic abnormalities and the size of genome are also associated with prognosis. Meanwhile, cases with ASXL1, DNMT3A, NRAS, SETBP1, CBL and RUNX1 mutations may have inferior prognoses, but only ASXL1 mutations were confirmed to be independent predictors of the patient outcome and were included in three prognostic models. Novel treatment targets related to the various gene mutations are emerging. Therefore, this review provides new insights to explore the correlations among gene mutations, clinical phenotypes, prognosis, and novel drugs in CMML.

Indexed as

MutationAntineoplastic AgentsCarrier ProteinsChromosome AberrationsCore Binding Factor Alpha 2 SubunitDioxygenasesDNA-Binding ProteinsDNA MethylationDNA Methyltransferase 3AEpigenesis, GeneticEpigenetic RepressionGenes, rasGenome SizeGTP PhosphohydrolasesHumansLeukemia, Myeloid, AcuteAntineoplastic AgentsASXL1 protein, humanCarrier ProteinsCBL protein, humanCore Binding Factor Alpha 2 SubunitDioxygenasesDNA-Binding ProteinsDNA Methyltransferase 3ADNMT3A protein, humanGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanNuclear ProteinsProto-Oncogene Proteins c-cblRepressor ProteinsRUNX1 protein, humanSerine-Arginine Splicing FactorsSETBP1 protein, humanSRSF2 protein, humanTET2 protein, humanChronic myelomonocytic leukemiaGene mutationsNovel drugsPrognosis

Identifiers

PMID33861431
OpenAlexW3154245291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.